Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
Board Member and Director, Africa Fighting Malaria (United States and South Africa), 2000-present
Fellow, 2000-present; Founder and Director, Environmental Unit, 1993-2003, Institute of Economic Affairs
Fellow, 2003; Director, 2001-2003, International Policy Network
Founder, Frederick Bastiat International Journalism Prize, 2001
Cofounder and Director, European Science and Environment Forum, 1995-2001
Research Analyst, Warburg Securities and Charles Stanley & Co., 1986-89
Ph.D., economics; MPhil., land economy, University of Cambridge
MSc., environmental and resource management, University College, London University
There is a growing cause for alarm as evidence of corner-cutting mounts-particularly among Indian generics manufacturers-and the products that are actually sold on the market don't maintain the same quality standards as those that received approval. Only time will tell how lethal the consequences of this corner cutting will be.
At this event, Dinesh Thakur will discuss his experiences and the wider problems of Indian drug quality. Pharmaceutical and medical experts will then discuss Thakur’s remarks and the safety of US and international drugs.
The reach of the Indian pharmaceutical industry is enormous. India supplies a large and increasing amount of the generic drugs sold globally, and the country is home to over 150 drug manufacturing facilities approved by the US Food and Drug Administration1—including many run by multinational players.
Indian companies exported generic drugs worth $4.2 billion to the United States last year, and demand is accelerating. But so too are safety concerns about these medicines -- and they’re not being addressed by the Indian government.
Tanzanian authorities and INTERPOL have just made a major seizure of fake and substandard drugs. While good news, it's a stark reminder that Africa remains ground zero in the global war on bad medicine.